Search results for Alz:ca

Alzai Health Corp. Files Final Prospectus in Connection With Initial Public Offering

Not for distribution to U.S. Newswire services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. Securities...

Allogene: Early ALPHA3 Data Suggests Potential Paradigm Shift For Cema-Cel In LBCL

Alamar Biosciences: Looking For An Early Detection

Allied Gold Non-GAAP EPS of $0.56, revenue of $209.27M

Amprion working to expand access globally to alpha-synuclein protein test

Amprion is partnering with Macquarie University in Australia to expand access to its SAAmplify-alphaSYN test, which detects abnormal alpha-synuclein protein in people with suspecte...

Analyst Report: Alcon AG

Analyst Report: Alcon AG

IGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA Trial as Enrollment Advances Toward Completion

Behavioral neurology expertise and expanded patient access support final phase of recruitment in Alzheimer's agitation study

IGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA Trial as Enrollment Advances Toward Completion

Behavioral neurology expertise and expanded patient access support final phase of recruitment in Alzheimer's agitation study

Alterity Therapeutics Limited (ATHE) Discusses Phase II Data and Development Strategy for ATH434 in Multiple System Atro...

Medicenna Therapeutics Corp. (MDNA:CA) Presents at 2026 Bloom Burton & Co. Healthcare Investor Conference - Slidesho...

The Key Biomarkers Changing How and When We Diagnose Alzheimer’s Disease

Innovations in biomarker science, particularly in cerebrospinal fluid (CSF) and blood, are expanding Alzheimer’s testing beyond specialty care. The post The Key Biomarkers Changin...

Astellas Pharma Inc. (ALPMY) Discusses R&D Strategy and Focus Areas in Innovative Healthcare - Slideshow

Transforming neurodegenerative disease treatment

Discover how Cognition Therapeutics is redefining hope for Alzheimer’s and Dementia with Lewy bodies [JG1] with innovative, accessible therapies.

IGC Pharma to Present Tau-PET Biomarker Research at 2026 Global Tau Conference

Research highlights advanced imaging analytics that may support Alzheimer's disease monitoring, patient stratification, and future therapeutic development.

Allogene Therapeutics, Inc. (ALLO) Discusses Interim Futility Analysis from Pivotal Phase II ALPHA 3 Trial in First-Line...

Extendicare Inc. (EXE:CA) Shareholder/Analyst Call - Slideshow

Alzheimer’s Risk Gene May Drive Aggressive ALS

The APOE ε4 variant heavily influences how toxic phosphorylated TDP-43 (pTDP-43) pathology migrates across the central nervous system.

The ALS Association Supports Reintroduction of ACT for ALS Bill to Accelerate Treatments and Expand Access for People Li...

Treatments Are Within Reach: Reintroduced ACT for ALS Bill Would Help Get Them to People Living with ALS Faster

IGC Pharma Reaches 80% Enrollment in Phase 2 CALMA Trial, Entering Final Phase Ahead of Enrollment Completion and Data R...

IGC Pharma reaches 80% enrollment in its Phase 2 CALMA Alzheimer’s trial, advancing toward completion, data readout, and a major clinical catalyst in 2026.

Amylyx (AMLX) Q1 2026 Earnings Transcript

Image source: The Motley Fool. DATEThursday, May 7, 2026 at 8 a.m. ETCALL PARTICIPANTSCo-Chief Executive Officer — Justin KleeCo-Chief Executive Officer — Joshua CohenChief Commer...

47-Year-Old Mom With Early-Onset Alzheimer’s Shares Her First Symptoms

Only 2 years after giving birth to her son, Gunnar, at age 44, Staci Marklin received a diagnosis that would change her and her family’s lives forever. In October 2024, she was dia...

Allianz: The Risks Continue To Outweigh The Upside

Neuronal AcCoA Signaling Linked to Autophagy Defects in Alzheimer’s

Neurons and glial cells utilize a specialized metabolic mechanism centered on leucine-derived acetyl-coenzyme A (AcCoA) to regulate the master growth hub, mTORC1.